One concrete data point for the thread. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.
One thing that is still open after james_edin’s answer:
Whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is?
TrialTracker_MD said:With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most…
There is a second half to this that has not been said yet. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsReporting back.
Resolved, and the thing that resolved it was the least interesting suggestion in the thread. Writing that down for the next person who wants the interesting answer.
Dr.PulmRoch said:The useful move here is to separate what is established from what is widely repeated.
True, and it depends on a baseline nobody has stated. Without knowing where someone started, the same number can be an excellent result or a disappointing one.